Tongren-Dahuoluo Bolus
ApprovedSmall molecule
Tongren-Dahuoluo Bolus is one of 26 small molecule programs targeting Osteoarthritis. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
25
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
778 competitors in Osteoarthritis
#DrugCompanyPhaseTrials
1Tongren-Dahuoluo Bolus
GGuang'anmen Hospital of China Academy of Chinese Medical Sciences
Approved
Toradol
RochePreclinical
Cataflam
NovartisPreclinical
Platelet Rich Plasma
ZZagazig University
Preclinical
Voltaren
CCerimon Pharmaceuticals
Preclinical
Enbrel
IImmunex
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Protonix
WWyeth-Lederle Vaccines
Preclinical
Paracetamol
GSKPreclinical
Naproxen Sodium
BayerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Osteoarthritis1 trial
Efficacy and Safety of Tongren-Dahuoluo Bolus in Patients with Knee Osteoarthritis
Not yet recruiting·GGuang'anmen Hospital of China Academy of Chinese Medical Sciences·Phase 4·NCT06674759·72 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Tongren-Dahuoluo Bolus. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details